Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact Gail Kudo to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- Novartis Investigative Site, Los Angeles, California, 90033
- Novartis Investigative Site, Los Angeles, California, 90033
-
Iowa
- Novartis Investigative Site, Iowa City, Iowa, 52242
-
Taiwan
- Novartis Investigative Site, Niaosong Township, 83301
- Novartis Investigative Site, Niaosong Township, 83301
-
Germany
- Novartis Investigative Site, Freiburg, 79104
- Novartis Investigative Site, Freiburg, 79104
- Novartis Investigative Site, Marburg, 35039
- Novartis Investigative Site, Marburg, 35039
-
Cedex
- Novartis Investigative Site, Rouen, Cedex, 76031
- Novartis Investigative Site, Rouen, Cedex, 76031
Powered by
SC CTSI